The CML blast crisis cell line K562, harboring a BCR-ABL1 fusion mutation, and the eosinophilic leukemia cell line EOL-1 (harboring a FIP1L1-PDGFRA mutation), were treated with crenolanib as described above. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.